These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 3601579

  • 1. Disorders of biotransformation during the progression of alcoholic liver disease.
    Horváth T, Pár A, Past T, Beró T, Tapsonyi Z, Kádas I.
    Acta Med Hung; 1986; 43(4):351-7. PubMed ID: 3601579
    [Abstract] [Full Text] [Related]

  • 2. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
    Horváth T, Past T, Tatai Z, Pár A, Kádas I, Tapsonyi Z, Jávor T.
    Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A, Horváth T, Beró T, Kádas I, Pakodi F, Jávor T.
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [Abstract] [Full Text] [Related]

  • 4. Drug metabolism in alcoholic liver disease.
    Horváth T, Pár A, Past T, Tapsonyi Z, Ruzsa C, Kádas I, Jávor T.
    Acta Med Acad Sci Hung; 1982; 39(3-4):169-77. PubMed ID: 7185242
    [No Abstract] [Full Text] [Related]

  • 5. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
    Horváth T, Pár A, Beró T, Kádas I, Fábián C, Jávor T.
    Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
    [Abstract] [Full Text] [Related]

  • 6. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
    Traeger A, Horváth T, Rechenbach C, Jávor T.
    Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacokinetics of antipyrine in viral and alcoholic lesions of the liver].
    Tsyrkunov VM, Bushma MI, Garelik PV, Novitskiĭ GK, Zavodnik LB.
    Klin Med (Mosk); 1989 Feb; 67(2):87-9. PubMed ID: 2724896
    [Abstract] [Full Text] [Related]

  • 8. [Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases].
    Truckenbrodt J, Kraul H, Huster A, Töpfer R, Henschel L, Hoffmann A, Reinhardt M, Jorke D.
    Gastroenterol J; 1990 Feb; 50(4):179-82. PubMed ID: 2091673
    [Abstract] [Full Text] [Related]

  • 9. [Alcohol and drug biotransformation].
    Klinger W.
    Z Gesamte Inn Med; 1981 Aug 15; 36(16):543-7. PubMed ID: 7293289
    [Abstract] [Full Text] [Related]

  • 10. Impairment of drug elimination in patients with liver disease.
    Narang AP, Datta DV, Mathur VS.
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan 15; 23(1):28-32. PubMed ID: 3988389
    [Abstract] [Full Text] [Related]

  • 11. [Kinetic analysis of bromosulfophthalein in alcoholic liver disease].
    Biagi P, Brettoni A, Bocchini S, Mellone G, Venier A.
    Quad Sclavo Diagn; 1981 Dec 15; 17(4):533-42. PubMed ID: 7347831
    [Abstract] [Full Text] [Related]

  • 12. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
    Pár A, Róth E, Rumi G, Kovács Z, Nemes J, Mózsik G.
    Orv Hetil; 2000 Jul 23; 141(30):1655-9. PubMed ID: 10962902
    [Abstract] [Full Text] [Related]

  • 13. Prognosis for the patients with alcoholic and nonalcoholic liver disease.
    Colić-Cvrlje V, Naumovski-Mihalić S, Prskalo M, Colić A, Cvjeticanin B, Sabarić B.
    Coll Antropol; 2000 Jun 23; 24(1):249-52. PubMed ID: 10895552
    [Abstract] [Full Text] [Related]

  • 14. Drug metabolism in drug-induced liver diseases: pathogenetic role of active metabolites.
    Horváth T, Past T, Németh A, Kádas I, Hoffmann-Traeger A, Rechenbach C, Jávor T.
    Acta Physiol Hung; 1989 Jun 23; 73(2-3):293-304. PubMed ID: 2596319
    [Abstract] [Full Text] [Related]

  • 15. Expression of the beta 1 chain (CD29) of integrins and CD45 in alcoholic liver disease. The VA Cooperative Study Group No. 275.
    Chedid A, Mendenhall CL, Moritz TE, French SW, Chen TS, Morgan TR.
    Am J Gastroenterol; 1993 Nov 23; 88(11):1920-7. PubMed ID: 7694454
    [Abstract] [Full Text] [Related]

  • 16. [Alcoholic liver disease].
    Waluga M, Hartleb M.
    Wiad Lek; 2003 Nov 23; 56(1-2):61-70. PubMed ID: 12901271
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease.
    Gonzàlez-Quintela A, Alende MR, Gamallo R, Gonzàlez-Gil P, López-Ben S, Tomé S, Otero E, Torre JA.
    Hepatogastroenterology; 2003 Nov 23; 50(54):2121-6. PubMed ID: 14696478
    [Abstract] [Full Text] [Related]

  • 19. [Final products of lipid peroxidation in various liver diseases of alcoholic etiology].
    Loginov AS, Dzhalalov KD, Erin AN, Prilipko LL.
    Biull Eksp Biol Med; 1986 Jan 23; 101(1):26-8. PubMed ID: 3942811
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.